• Login
Forest Laboratories
Divisions and Subsidiaries
  • Forest Pharmaceuticals
  • Forest Laboratories Europe
  • Cerexa, Inc.
  • Forest Laboratories Canada Inc.
  • About Forest
        • Overview
          • Forest identifies, develops, and delivers therapies that make a meaningful difference in people's lives
        • Products
        • Research
        • News
  • Investor Center
        • Overview
          • Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises
        • Annual Reports
        • Stock Information
        • Webcasts &
          Presentations
  • Partnerships
        • Overview
          • Forest partners with biotech and pharmaceutical companies to develop and bring promising new medicines to market
        • Capabilities
  • Careers
        • Overview
          • Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine
        • Job Search
  • About Forest
  • Products
  • Research
  • News
    • Media Resources
    • Press Release Archive
    • All Press Releases
    • Business Development News
    • Corporate News
    • Financial News
    • Product News
    • R&D News

R&D News

  • 03.04.2008
    Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
  • 02.05.2008
    Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
  • 11.01.2007
    UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
  • 10.15.2007
    Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
  • 09.18.2007
    Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
  • 09.04.2007
    Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
  • 05.31.2007
    Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
  • 05.22.2007
    Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
  • 05.21.2007
    Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
  • 05.01.2007
    Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
  • « first
  • ‹ previous
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • next ›
  • last »

ABOUT FOREST

With a unique partnership-focused business model and a strong track record of commercial achievement, Forest has built a pharmaceutical business for today's environment. The Company is fulfilling its objective of making a meaningful difference in patients' lives through an expanded and diversified product portfolio and the most robust pipeline in our history.

CAREERS AT FOREST

Forest employees are driven by a shared passion to help improve patients' lives through medicine. Forest offers a variety of opportunities for experienced professionals, sales professionals, graduate students, and others to build their careers in a collaborative environment. Learn more about joining our team.

 

  • Legal Statement
  • Privacy Policy
  • Contact Us
  • Site Map
© Forest Laboratories, Inc.    085-13000018 6/13